New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
07:17 EDTEPZMEpizyme files to sell 4.2M shares of common stock
Citigroup, Cowen and Company, LLC and Leerink Partners LLC are acting as joint book-running managers for the offering. JMP Securities LLC, Wedbush Securities Inc. and BTIG LLC are acting as co-managers for the offering
News For EPZM From The Last 14 Days
Check below for free stories on EPZM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 24, 2014
08:03 EDTEPZMEpizyme receives notice of allowance in U.S. for cancer treatment patent
Epizyme has been granted a notice of allowance by the USPTO for claims that cover methods of treating cancer with EZH2 inhibitors. The patent will expire in 2033. Epizyme's small molecule inhibitor of EZH2, EPZ-6438 (E7438), is currently being developed in a Phase 1/2 clinical trial in patients with advanced solid tumors or relapsed or refractory B-cell lymphoma. In 2014, Epizyme plans to initiate two proof of concept studies with EPZ-6438, pending Phase 1 completion, one in non-Hodgkin lymphoma patients with EZH2 point mutations and one in synovial sarcoma patients. EPZ-6438 is being developed in collaboration with Eisai Inc.
April 22, 2014
08:06 EDTEPZMEpizyme receives $4M milestone and license payment
Epizyme announced the achievement of the lead candidate milestone for the third of the three histone methyltransferase targets in the company's collaboration with GSK and is receiving $4M in milestone and license payments. Previously, Epizyme announced the achievement of a $4M development candidate milestone for the first GSK collaboration target in January and a $2M lead candidate selection milestone for the second GSK collaboration target in February.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use